Redefining Possibilities with Innovative, Effective, and Safe Off-the Shelf Cell Therapies
Vision
At Eterna, our vision is to improve the lives of patients with difficult-to-treat diseases through our innovative, effective, and safe, but accessible cellular therapies.
Mission
Eterna is focused on developing innovative off-the-shelf cellular therapies, leveraging iPSC-derived mesenchymal stem cells (iMSCs) to target solid tumors.
Currently, we are focusing on developing iPSC-derived MSCs (iMSCs) that express critical factors, such as pro-inflammatory cytokines.
Partner with us
MSCs: Therapeutic Potential and Current Limitations:
- MSCs are multipotent stromal cells capable of differentiating into various cell types like bone, muscle, and connective tissue
- MSCs secrete immunomodulatory factors, making them a promising for treating immune and inflammatory diseases (Zhao et al., 2016)
- Differences in genetic background, donor age, and tissue origin (bone marrow vs. adipose tissue) contribute to MSC heterogeneity and inconsistent therapeutic outcomes (Olmedo-Moreno et al., 2022; Choudhery et al., 2022; Wruck et al., 2021)
- MSCs exhibit batch-to-batch variability, limited proliferative capacity, and early senescence in culture, affecting the consistency of MSCbased therapies (Olmedo-Moreno et al., 2022; Choudhery et al., 2022; Wruck et al., 2021)
...
See More
Induced Pluripotent Stem Cell (iPSC)-derived MSCs (iMSCs)
- iPSC-derived MSCs (iMSCs) offer a solution to overcome the limitations of traditional MSC therapies (Zhang et al., 2021; Dupuis et al., 2021)
- iMSCs are generated from homogeneous, well characterized cell lines under controlled conditions (Zhang et al., 2021; Dupuis et al., 2021)
- They are a stable and rejuvenated source for allogeneic therapies (Bruschi et al., 2022)
...
See More
Eterna’s Pro inflammatory Cytokine (e.g. IL-7+IL15) Secreting iPSC-derived MSCs (iMSCs) Therapy
- Eterna’s iMSC therapy is developed through reprogramming iPSCs using synthetic RNA molecules encoding reprogramming factors
- The company’s proprietary mRNA-based platform enhances iPSC generation, enabling a scalable, off-the-shelf iMSC product. Our initial iMSC product is designed to deliver IL-7/IL-15 selectively to tumors, limiting systemic exposure and potential toxicity while significantly enhancing T-cell anti-tumor activity.
...
See More
In Development
Eterna will first focus on advancing its lead product candidate ERNA-101, which leverages induced pluripotent stem cells (iPSC)-derived mesenchymal stem cells (iMSCs) over expressing critical factors, such as pro-inflammatory cytokines IL-7 and IL-15 in advanced solid tumors.
Our Collaborations
Watch to learn about our collaboration with Lineage